Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Liso-Cel Analysis Shows Feasibility of Outpatient CAR T-Cell Therapy

Liso-Cel Analysis Shows Feasibility of Outpatient CAR T-Cell Therapy

February 20th 2020

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

February 20th 2020

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Assessing Treatment Strategies ALK+ Lung Cancer

Assessing Treatment Strategies ALK+ Lung Cancer

February 11th 2020

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer

February 11th 2020

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

February 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

Dr. Wakelee on Immediate Therapy Options in Lung Cancer

Dr. Wakelee on Immediate Therapy Options in Lung Cancer

February 10th 2020

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

February 10th 2020

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Should EGFR TKI Use Expand in Frontline NSCLC?

Should EGFR TKI Use Expand in Frontline NSCLC?

February 10th 2020

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

February 10th 2020

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Therapeutic Advances Promote Personalized Medicine in Advanced NSCLC

Therapeutic Advances Promote Personalized Medicine in Advanced NSCLC

February 10th 2020

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Finding the Immunotherapy Finish Line Remains a Challenge in NSCLC

Finding the Immunotherapy Finish Line Remains a Challenge in NSCLC

February 9th 2020

Based on available data, treatment is not that obvious for patients with metastatic non–small cell lung cancer who are tolerating treatment well and have either a complete or partial response to therapy.

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

February 9th 2020

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Immunotherapy Shows Promise in Cervical Cancer Treatment

Immunotherapy Shows Promise in Cervical Cancer Treatment

February 9th 2020

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer

February 9th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

February 9th 2020

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.

Immunotherapy Restructures the SCLC Treatment Landscape

Immunotherapy Restructures the SCLC Treatment Landscape

February 9th 2020

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.

Optimal Immunotherapy Sequencing Remains Elusive in Lung Cancer

Optimal Immunotherapy Sequencing Remains Elusive in Lung Cancer

February 9th 2020

The potential therapeutic benefits of immune checkpoint inhibitors as monotherapy as well as in combination with chemotherapy for patients with non–small cell lung cancer depend greatly on the timing of treatment initiation. However, for patients with EGFR, ALK, and other actionable mutations, identifying the optimal combination is a hurdle.

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

February 9th 2020

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.

Novel PARP Combinations Boost Responses in Ovarian Cancer

Novel PARP Combinations Boost Responses in Ovarian Cancer

February 9th 2020

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

Building on Momentum Is Vital in Lung Cancer

Building on Momentum Is Vital in Lung Cancer

February 8th 2020

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

PARP Inhibitors May Have Benefit in BRCA-Mutant Endometrial Cancers

PARP Inhibitors May Have Benefit in BRCA-Mutant Endometrial Cancers

February 8th 2020

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

February 8th 2020

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer

Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer

February 8th 2020

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Treatment Options Abound in Platinum-Sensitive Ovarian Cancer

Treatment Options Abound in Platinum-Sensitive Ovarian Cancer

February 8th 2020

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.